or Try an Advanced Search...

    Technical Analysis for KYTX - Kyverna Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 14.47 -0.89% -0.13
    KYTX closed up 15.32 percent on Thursday, May 9, 2024, on 70 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong N/A Down Down
    Historical KYTX trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup -0.89%
    Bullish Engulfing Bullish -0.89%
    Wide Bands Range Expansion -0.89%
    Oversold Stochastic Weakness -0.89%
    New 52 Week Closing Low Bearish 14.30%
    New 52 Week Low Weakness 14.30%
    Wide Bands Range Expansion 14.30%
    Down 3 Days in a Row Weakness 14.30%
    Oversold Stochastic Weakness 14.30%
    New 52 Week Closing Low Bearish 6.01%
    Older End-of-Day Signals for KYTX ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance 4 minutes ago
    Down 1% 4 minutes ago
    Rose Above Previous Day's High 17 minutes ago
    Rose Above 10 DMA 17 minutes ago
    Up 1% 17 minutes ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    KYTX Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis

    Is KYTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 11 Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
    Mar 29 First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
    Mar 26 Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
    Mar 14 Why That Hot Biotech IPO Could Be a Winner
    Mar 8 Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
    Mar 7 How Kyverna is positioned for success on autoimmune therapy: CEO
    Feb 12 Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
    Feb 12 IPO Roundup: Wetouch Technology, Amphitrite Digital, and more
    Feb 8 Kyverna Therapeutics stock rallies 59% following $319M IPO
    See more KYTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 35.06
    52 Week Low 12.26
    Average Volume 398,542
    200-Day Moving Average 0.00
    50-Day Moving Average 22.54
    20-Day Moving Average 17.27
    10-Day Moving Average 14.74
    Average True Range 1.59
    RSI (14) 35.48
    ADX 52.64
    +DI 10.29
    -DI 33.59
    Chandelier Exit (Long, 3 ATRs) 20.09
    Chandelier Exit (Short, 3 ATRs) 17.03
    Upper Bollinger Bands 23.40
    Lower Bollinger Band 11.14
    Percent B (%b) 0.28
    BandWidth 70.99
    MACD Line -2.61
    MACD Signal Line -2.52
    MACD Histogram -0.0826
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.87
    Resistance 3 (R3) 17.56 16.15 17.33
    Resistance 2 (R2) 16.15 15.32 16.31 17.14
    Resistance 1 (R1) 15.38 14.81 15.77 15.69 16.96
    Pivot Point 13.97 13.97 14.17 14.13 13.97
    Support 1 (S1) 13.20 13.14 13.59 13.51 12.24
    Support 2 (S2) 11.79 12.63 11.95 12.06
    Support 3 (S3) 11.02 11.79 11.88
    Support 4 (S4) 11.33